biostudies-literatureUnknown18(2)Venegas-Rodriguez RThis paper presents the results of an observational and retrospective study on the therapeutic effects of Jusvinza, an immunomodulatory peptide with anti-inflammatory properties for critically ill COVID-19 patients. This peptide induces regulatory mechanisms on the immune response in experimental systems and in patients with Rheumatoid Arthritis. Exploratory research in COVID-19 patients revealed that Jusvinza promotes clinical and radiological improvement. The aim of this study is to describe the clinical outcome and variations of several inflammatory biomarkers in a cohort of critically ill COVID-19 patients, divided into two groups during the observational research: one group received Jusvinza and the other did not. Research physicians extracted the patients´ data from their hospital's PloS onee0281111https://www.ebi.ac.uk/biostudies/studies/S-EPMC9894446biostudies-literatureJusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study.PMC9894446Rosario-Cruz LPerez-Aguilera LDominguez-Horta MDCSantana-Sanchez RVenegas-Rodriguez RMartinez-Donato GGuillen-Nieto GPena-Ruiz RHernandez-Cedeno MGrecesqui-Cruz ISerrano-Diaz ARittoles Navarro ASegura-Fernandez AfalseJusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study.This paper presents the results of an observational and retrospective study on the therapeutic effects of Jusvinza, an immunomodulatory peptide with anti-inflammatory properties for critically ill COVID-19 patients. This peptide induces regulatory mechanisms on the immune response in experimental systems and in patients with Rheumatoid Arthritis. Exploratory research in COVID-19 patients revealed that Jusvinza promotes clinical and radiological improvement. The aim of this study is to describe the clinical outcome and variations of several inflammatory biomarkers in a cohort of critically ill COVID-19 patients, divided into two groups during the observational research: one group received Jusvinza and the other did not. Research physicians extracted the patients´ data from their hospital's 2023-01-01T00:00:00Z20232025-04-26T18:10:46.109Z2025-04-06T15:43:12.97ZS-EPMC98944463673032510.1371/journal.pone.0281111